CYP27A1 and Miyoshi myopathy: A retrospective analysis of 106 patients with refractory and recurrent MM was conducted, while 99 patients were prospectively included.22 The results showed that bone resorption marker β-CTX decreased compared to before in patients who responded to the combination of lenalidomide and dexamethasone (RD) regimen, but bone formation indicators were not affected.